Gilead, Royalty Pharma acquire Emtriva rights for $525M

Gilead Sciences and Royalty Pharma have agreed to pay Emory University $525 million for the university's royalty rights to the HIV drug Emtriva. Foster City, California-based Gilead's share of that is $341 million for 65 percent of the royalty rights with the rest coming from New York-based Royalty Pharma. Emory quickly labeled the deal as the largest intellectual property rights payoff involving an American university. Emory says it will put the money to use in future scientific research and development projects.

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.